UPDATE: Piper Jaffray Lowers PT to $87 on Allergan
A report from Piper Jaffray reiterates its Neutral rating and lowers its price target from $89 to $87 on Allergan (NYSE: AGN).
The report states, “…cautious management commentary on the aesthetics business in North America reinforces our view that AGN shares are nearly fully valued. Our price target is now $87, down from $89, reflecting slight downward revisions to our EPS estimates."
AGN closed yesterday at $86.96.
(c) 2012 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We're Loving
